克罗恩病中抗肿瘤坏死因子药物的最新进展。
Update on anti-tumor necrosis factor agents in Crohn disease.
作者信息
Singh Siddharth, Pardi Darrell S
机构信息
Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, 200 First Street South West, Rochester, MN 55905, USA.
Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, 200 First Street South West, Rochester, MN 55905, USA.
出版信息
Gastroenterol Clin North Am. 2014 Sep;43(3):457-78. doi: 10.1016/j.gtc.2014.05.008. Epub 2014 Jun 24.
Anti-tumor necrosis factor-α (TNF) agents, including infliximab, adalimumab, and certolizumab pegol, are effective medications for the management of moderate to severe Crohn disease (CD). They are effective in inducing and maintaining clinical remission, inducing mucosal healing, improving quality of life, and reducing the risk of hospitalization and surgery in adult and pediatric patients with CD. Future research into comparative effectiveness of different agents, as well as better understanding of predictors of response, is warranted to allow optimization of therapeutic response.
抗肿瘤坏死因子-α（TNF）药物，包括英夫利昔单抗、阿达木单抗和聚乙二醇化赛妥珠单抗，是治疗中度至重度克罗恩病（CD）的有效药物。它们在诱导和维持临床缓解、诱导黏膜愈合、改善生活质量以及降低成年和儿科CD患者的住院和手术风险方面均有效。有必要对不同药物的相对疗效进行进一步研究，并更好地了解反应预测因素，以优化治疗反应。
Zotero 插件